1
|
Karakoese Z, Le-Trilling VTK, Schuhenn J, Francois S, Lu M, Liu J, Trilling M, Hoffmann D, Dittmer U, Sutter K. Targeted mutations in IFNα2 improve its antiviral activity against various viruses. mBio 2023; 14:e0235723. [PMID: 37874130 PMCID: PMC10746204 DOI: 10.1128/mbio.02357-23] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/06/2023] [Accepted: 09/07/2023] [Indexed: 10/25/2023] Open
Abstract
During viral infections, type I interferons (IFN) are induced and play a key role in counteracting initial viral spread. Twelve different human IFNα subtypes exist that bind the same receptor; however, they elicit unique host responses and display distinct potencies of antiviral activities. Our previous studies on human immunodeficiency virus (HIV) and hepatitis B virus (HBV) demonstrated that the clinically used IFNα2 is not the most effective one among the IFNα subtypes. By sequence modeling, we identified a region in helix B with mainly conserved residues at the outside facing IFNAR1, but variable residues at the inside facing the core of IFNα, potentially representing a putative tunable anchor to tune pleiotropic IFN responses. Using site-directed mutagenesis, various mutations were introduced into the IFNα2b backbone targeting sites which are important for binding to IFNAR1 and IFNAR2, the putative tunable anchor, or outside these three regions. Selected mutations were based on sequence differences to high antiviral subtypes IFNα6 and IFNα14. Treatment assays against HBV and HIV identified several critical residues for the antiviral activity of IFNα mainly in the IFNAR1 binding region. Combined mutations of the IFNα2 IFNAR1/2 binding sites or the IFNAR1 binding region plus the putative tunable anchor by those of IFNα14 further augmented activation of different downstream signaling cascades providing a molecular correlate for the enhanced antiviral activity. We describe here important functional residues within IFNα subtype molecules, which enabled us to design novel and innovative drugs that may have the potential to be used in clinical trials against a variety of different viral infections.IMPORTANCEThe potency of interferon (IFN)α to restrict viruses was already discovered in 1957. However, until today, only IFNα2 out of the 12 distinct human IFNα subtypes has been therapeutically used against chronic viral infections. There is convincing evidence that other IFNα subtypes are far more efficient than IFNα2 against many viruses. In order to identify critical antiviral residues within the IFNα subtype sequence, we designed hybrid molecules based on the IFNα2 backbone with individual sequence motifs from the more potent subtypes IFNα6 and IFNα14. In different antiviral assays with HIV or HBV, residues binding to IFNAR1 as well as combinations of residues in the IFNAR1 binding region, the putative tunable anchor, and residues outside these regions were identified to be crucial for the antiviral activity of IFNα. Thus, we designed artificial IFNα molecules, based on the clinically approved IFNα2 backbone, but with highly improved antiviral activity against several viruses.
Collapse
Affiliation(s)
- Zehra Karakoese
- University Hospital Essen, University of Duisburg-Essen, Institute for Virology, Essen, Germany
- University Hospital Essen, University of Duisburg-Essen, Institute for Translational HIV Research, Essen, Germany
| | | | - Jonas Schuhenn
- University Hospital Essen, University of Duisburg-Essen, Institute for Virology, Essen, Germany
| | - Sandra Francois
- University Hospital Essen, University of Duisburg-Essen, Institute for Virology, Essen, Germany
| | - Mengji Lu
- University Hospital Essen, University of Duisburg-Essen, Institute for Virology, Essen, Germany
- Joint International Laboratory of Infection and Immunity, Huazhong University of Science and Technology, Wuhan, China
| | - Jia Liu
- Joint International Laboratory of Infection and Immunity, Huazhong University of Science and Technology, Wuhan, China
- Department of Infectious Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
| | - Mirko Trilling
- University Hospital Essen, University of Duisburg-Essen, Institute for Virology, Essen, Germany
- Joint International Laboratory of Infection and Immunity, Huazhong University of Science and Technology, Wuhan, China
| | - Daniel Hoffmann
- Joint International Laboratory of Infection and Immunity, Huazhong University of Science and Technology, Wuhan, China
- Research Group Bioinformatics, Faculty of Biology, University of Duisburg-Essen, Essen, Germany
| | - Ulf Dittmer
- University Hospital Essen, University of Duisburg-Essen, Institute for Virology, Essen, Germany
- University Hospital Essen, University of Duisburg-Essen, Institute for Translational HIV Research, Essen, Germany
- Joint International Laboratory of Infection and Immunity, Huazhong University of Science and Technology, Wuhan, China
| | - Kathrin Sutter
- University Hospital Essen, University of Duisburg-Essen, Institute for Virology, Essen, Germany
- University Hospital Essen, University of Duisburg-Essen, Institute for Translational HIV Research, Essen, Germany
- Joint International Laboratory of Infection and Immunity, Huazhong University of Science and Technology, Wuhan, China
| |
Collapse
|
2
|
Harris T, Tracy K, Francois S, Tucker W, Ukita R, Johnson C, DeVries S, Cortelli M, Cardwell N, Do N, Pasrija C, Demarest C, Alexopoulos S, Shaver C, Bacchetta M. Autologous Blood Re-Exposure Does Not Invoke Hyperacute Rejection in a Human Lung after Xenogeneic Cross-Circulation. J Heart Lung Transplant 2023. [DOI: 10.1016/j.healun.2023.02.1540] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/05/2023] Open
|
3
|
Samson M, Nicolas B, Guilhem A, Greigert H, Ciudad M, Cladiere C, Straub C, Blot M, Piroth L, Rogier T, Devilliers H, Manckoundia P, Ghesquiere T, Francois S, Lakomy D, Audia S, Bonnotte B. L’augmentation du pourcentage de lymphocytes Th17 est associée à un risque d’évolution vers une forme grave d’infection à SARS-CoV-2. Rev Med Interne 2022. [PMCID: PMC9212761 DOI: 10.1016/j.revmed.2022.03.291] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
Introduction Depuis décembre 2019, plus de 20 millions de français ont été infectés par le SARS-CoV-2 et plus de 130 000 en sont décédés. La physiopathologie de cette infection n’est pas totalement élucidée. Il a été démontré qu’elle provoquait une importante sécrétion de cytokines pro-inflammatoires, en particulier d’interleukine-6 (IL-6) [1]. Lorsque les patients infectés sont hospitalisés, ils reçoivent généralement de la dexaméthasone et parfois un traitement anti-infectieux. Si la maladie s’aggrave, le tocilizumab peut être ajouté [2]. Actuellement, seule l’évolution clinique incite à débuter le tocilizumab, mais parfois trop tardivement. Il manque aux cliniciens un marqueur précoce leur permettant de prédire le risque d’aggravation de la maladie. Cette étude, menée chez des patients hospitalisés pour infection à SARS-CoV-2 pendant la 2e vague, avait pour objectif de rechercher un marqueur d’aggravation de la maladie en comparant la réponse lymphocytaire entre les patients évoluant vers une forme grave et les autres. Patients et méthodes Les patients hospitalisés pour infection à SARS-CoV-2 prouvée par RT-PCR datant de moins d’une semaine ont été inclus prospectivement dans cette étude monocentrique. Une infection grave était définie par un transfert en soins intensifs, en réanimation ou le décès. Des prélèvements sanguins ont été obtenus à l’admission à l’hôpital et avant de débuter la corticothérapie afin d’étudier les sous-populations lymphocytaires par cytométrie en flux et doser l’IL-6 plasmatique par immunofluorimétrie. Les données sont exprimées en nombre (%) ou médiane (espace inter-quartile). Résultats De septembre à décembre 2020, 37 patients (18 hommes, 19 femmes) hospitalisés pour infection à SARS-Cov2 ont été inclus : âge = 81,7 (70,3–87,5) ans, IMC = 25,7 (23,7–29) kg/m2, hypertension artérielle (54 %), diabète (24 %), dyslipidémie (35 %), tabagisme (24 %), cardiopathie ischémique (8 %), maladie cérébrovasculaire (11 %). La durée de suivi était de 10 (8–15) jours. Parmi les 37 patients inclus, 11 (30 %) ont présenté une infection à SARS-CoV-2 grave dont 4 transferts en réanimation et 8 décès. À l’admission, les patients ayant une infection évoluant vers une forme grave étaient plus âgés (p = 0,021), avaient une créatininémie plus élevée (p = 0,003) et une diminution du pourcentage de lymphocytes B (p = 0,04), de lymphocytes T (p = 0,009) et de lymphocytes T CD4+ (p = 0,004) circulants parmi les lymphocytes totaux comparativement aux patients dont l’évolution était favorable. Parmi les sous-populations lymphocytaires T étudiées (mémoires, naïfs, Th1, Th2, Th17, Treg, Tc1, Tc17, T CD8 cytotoxiques), il n’y avait pas de différence significative entre les deux groupes en dehors du pourcentage de lymphocytes Th17 à l’admission qui était deux fois plus élevé chez les patients dont l’infection évoluait vers une forme grave (0,44 vs 0,23 % des LT CD4 totaux ; p = 0,028). Chez les patients ayant une infection évoluant vers une forme grave, l’IL-6 plasmatique à l’admission était plus élevée (39 vs 13,1 pg/mL ; p = 0,018) et la CRP à l’admission avait tendance à être plus élevée sans atteindre le seuil de significativité (58 vs 18,5 mg/L ; p = 0,17). En analyse multivariée (régression logistique binaire comprenant les variables : âge, créatininémie, CRP, hémoglobine, lymphocytes T CD4, Th17, Treg activés (CD4 + CD45RA-FoxP3high), lymphocytes B, IL-6 sérique), la seule variable associée au risque d’évolution vers une forme grave de l’infection était le pourcentage de lymphocytes Th17 circulants (p = 0,034). L’aire sous la courbe de la courbe ROC évaluant la sensibilité et la spécificité du pourcentage de lymphocytes Th17 pour prédire une forme grave d’infection à SARS-CoV-2 chez un patient hospitalisé était de 0,75 (intervalle de confiance à 95 % : 0,56–0,95). Enfin, le fait d’avoir un pourcentage de lymphocytes Th17 > 0,435 % des lymphocytes T CD4 totaux au moment de l’admission en hospitalisation était associé à une moins bonne survie (p = 0,024). Conclusion Cette étude suggère qu’une élévation du pourcentage de lymphocytes Th17 chez des patients hospitalisés pour infection à SARS-CoV-2 augmente significativement le risque d’évolution vers une forme grave de la maladie. Ce résultat est cohérent avec le fait qu’il a été démontré que le tocilizumab, qui est efficace dans le traitement des formes graves de COVID-19 [2], inhibe la réponse lymphocytaire Th17 [3]. Ces données méritent d’être confirmées chez un plus grand nombre de patients afin de confirmer ce résultat car cette mesure pourrait permettre de mieux cibler la population de patients à qui proposer précocement un traitement par tocilizumab pour diminuer le risque d’évolution vers une forme grave d’infection à SARS-CoV-2.
Collapse
|
4
|
Schwerdtfeger M, Dickow J, Schmitz Y, Francois S, Karakoese Z, Malyshkina A, Knuschke T, Dittmer U, Sutter K. Immunotherapy With Interferon α11, But Not Interferon Beta, Controls Persistent Retroviral Infection. Front Immunol 2022; 12:809774. [PMID: 35126368 PMCID: PMC8810532 DOI: 10.3389/fimmu.2021.809774] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/05/2021] [Accepted: 12/29/2021] [Indexed: 01/24/2023] Open
Abstract
Type I Interferons (IFNs), including numerous IFNα subtypes and IFNβ, are key molecules during innate and adaptive immune responses against viral infections. These cytokines exert various non-redundant biological activities, although binding to the same receptor. Persistent viral infections are often characterized by increased IFN signatures implicating a potential role of type I IFNs in disease pathogenesis. Using the well-established Friend retrovirus (FV) mouse model, we compared the therapeutic efficacy of IFNα11 and IFNβ in acute and chronic retroviral infection. We observed a strong antiviral activity of both IFNs during acute FV infection, whereas only IFNα11 and not IFNβ could also control persistent FV infection. The therapeutic treatment with IFNα11 induced the expression of antiviral IFN-stimulated genes (ISG) and improved cytotoxic T cell responses. Finally, dysfunctional CD8+ T cells solely regained cytotoxicity after IFNα11 treatment. Our data provide evidence for opposing activities of type I IFNs during chronic retroviral infections. IFNβ was shown to be involved in immune dysfunction in chronic infections, whereas IFNα11 had a strong antiviral potential and reactivated exhausted T cells during persistent retroviral infection. In contrast, during acute infection, both type I IFNs were able to efficiently suppress FV replication.
Collapse
Affiliation(s)
| | - Julia Dickow
- Institute for Virology, University of Duisburg-Essen, Essen, Germany
| | - Yasmin Schmitz
- Institute for Virology, University of Duisburg-Essen, Essen, Germany
| | - Sandra Francois
- Institute for Virology, University of Duisburg-Essen, Essen, Germany
| | - Zehra Karakoese
- Institute for Virology, University of Duisburg-Essen, Essen, Germany
- Institute for Translational HIV Research, University of Duisburg-Essen, Essen, Germany
| | - Anna Malyshkina
- Institute for Virology, University of Duisburg-Essen, Essen, Germany
| | - Torben Knuschke
- Institute for Medical Microbiology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany
| | - Ulf Dittmer
- Institute for Virology, University of Duisburg-Essen, Essen, Germany
- Institute for Translational HIV Research, University of Duisburg-Essen, Essen, Germany
| | - Kathrin Sutter
- Institute for Virology, University of Duisburg-Essen, Essen, Germany
- Institute for Translational HIV Research, University of Duisburg-Essen, Essen, Germany
- *Correspondence: Kathrin Sutter,
| |
Collapse
|
5
|
Razanamahery J, Samson M, Guy J, Francois S, Emile J, Cohen Aubart F, Papo M, Haroche J, Audia S, Bonnotte B. La répartition des sous-populations monocytaire dans l’histiocytose est proche de la leucémie myélomonocytaire chronique, est corrélée au phénotype et à l’activité de la maladie. Rev Med Interne 2021. [DOI: 10.1016/j.revmed.2021.10.289] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
6
|
Kong H, Francois S, Smith S, Spraker M, Lawley L, Lee G, Chen K, Roberts J, Chen S. 300 Comparison of ItchyQuant, KidsItchyQoL and TweenItchyQoL: Pruritus assessment tools for 6-7-year-olds vs. 8-17 year olds. J Invest Dermatol 2021. [DOI: 10.1016/j.jid.2021.02.322] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
7
|
Ickler J, Francois S, Widera M, Santiago ML, Dittmer U, Sutter K. HIV infection does not alter interferon α/β receptor 2 expression on mucosal immune cells. PLoS One 2020; 15:e0218905. [PMID: 31935222 PMCID: PMC6959566 DOI: 10.1371/journal.pone.0218905] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/06/2019] [Accepted: 12/23/2019] [Indexed: 01/12/2023] Open
Abstract
The innate immune response induced by type I interferons (IFNs) plays a critical role in the establishment of HIV infection. IFNs are induced early in HIV infection and trigger an antiviral defense program by signaling through the IFNα/β receptor (IFNAR), which consists of two subunits, IFNAR1 and IFNAR2. Changes in IFNAR expression in HIV target cells, as well as other immune cells, could therefore have important consequences for initial HIV spread. It was previously reported that IFNAR2 expression is increased in peripheral blood CD4+ CXCR4+ T cells of HIV+ patients compared to HIV uninfected controls, suggesting that HIV infection may alter the IFN responsiveness of target cells. However, the earliest immune cells affected by HIV in vivo reside in the gut-associated lymphoid tissue (GALT). To date, it remains unknown if IFNAR expression is altered in GALT immune cells in the context of HIV infection and exposure to IFNs, including the 12 IFNα subtypes. Here, we analyzed the expression of surface bound and soluble IFNAR2 on Lamina propria mononuclear cells (LPMCs) isolated from the GALT of HIV- individuals and in plasma samples of HIV+ patients. IFNAR2 expression varied between different T cells, B cells and natural killer cells, but was not altered following HIV infection. Furthermore, expression of the soluble IFNAR2a isoform was not changed in HIV+ patients compared to healthy donors, nor in LPMCs after HIV-1 infection ex vivo. Even though the 12 human IFNα subtypes trigger different biological responses and vary in their affinity to both receptor subunits, stimulation of LPMCs with different recombinant IFNα subtypes did not result in any significant changes in IFNAR2 surface expression. Our data suggests that potential changes in the IFN responsiveness of mucosal immune cells during HIV infection are unlikely dictated by changes in IFNAR2 expression.
Collapse
Affiliation(s)
- Julia Ickler
- Institute for Virology, University Hospital Essen, University Duisburg-Essen, Essen, Germany
| | - Sandra Francois
- Institute for Virology, University Hospital Essen, University Duisburg-Essen, Essen, Germany
| | - Marek Widera
- Institute for Virology, University Hospital Essen, University Duisburg-Essen, Essen, Germany
| | - Mario L. Santiago
- Department of Medicine, University of Colorado Denver, Aurora, Colorado, United States of America
| | - Ulf Dittmer
- Institute for Virology, University Hospital Essen, University Duisburg-Essen, Essen, Germany
| | - Kathrin Sutter
- Institute for Virology, University Hospital Essen, University Duisburg-Essen, Essen, Germany
| |
Collapse
|
8
|
Dickow J, Francois S, Kaiserling RL, Malyshkina A, Drexler I, Westendorf AM, Lang KS, Santiago ML, Dittmer U, Sutter K. Diverse Immunomodulatory Effects of Individual IFNα Subtypes on Virus-Specific CD8 + T Cell Responses. Front Immunol 2019; 10:2255. [PMID: 31608062 PMCID: PMC6771563 DOI: 10.3389/fimmu.2019.02255] [Citation(s) in RCA: 20] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/03/2019] [Accepted: 09/06/2019] [Indexed: 12/21/2022] Open
Abstract
Clinical administration of Interferon α (IFNα) resulted in limited therapeutic success against some viral infections. Immune modulation of CD8+ T cell responses during IFNα therapy is believed to play a pivotal role in promoting viral clearance. However, these clinical studies primarily focused on IFNα subtype 2. To date, the immunomodulatory roles of the remaining 10-13 IFNα subtypes remains poorly understood, thereby precluding assessments of their potential for more effective treatments. Here, we report that virus-specific CD8+ T cell responses were influenced to various extents by individual IFNα subtypes. IFNα4, 6, and 9 had the strongest effects on CD8+ T cells, including antiproliferative effects, improved cytokine production and cytotoxicity. Interestingly, augmented cytokine responses were dependent on IFNα subtype stimulation of dendritic cells (DCs), while antiproliferative effects and cytotoxicity were mediated by IFNAR signaling in either CD8+ T cells or DCs. Thus, precise modulation of virus-specific CD8+ T cell responses may be feasible for specific antiviral immunotherapies through careful selection and administration of individual IFNα subtypes.
Collapse
Affiliation(s)
- Julia Dickow
- Institute for Virology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany
| | - Sandra Francois
- Institute for Virology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany
| | - Rouven-Luca Kaiserling
- Institute for Virology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany
| | - Anna Malyshkina
- Institute for Virology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany
| | - Ingo Drexler
- Institute of Virology, University Hospital Duesseldorf, Heinrich Heine University Duesseldorf, Düsseldorf, Germany
| | - Astrid Maria Westendorf
- Institute of Medical Microbiology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany
| | - Karl Sebastian Lang
- Institute for Immunology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany
| | - Mario L. Santiago
- Department of Medicine, University of Colorado Denver, Aurora, CO, United States
| | - Ulf Dittmer
- Institute for Virology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany
| | - Kathrin Sutter
- Institute for Virology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany
| |
Collapse
|
9
|
DeGrazia T, liu Y, Bradley B, Thompson C, Francois S, Chisolm S, Chen S, Feldman R. LB1101 Itch and quality of life impact in atopic dermatitis vs bullous pemphigoid. J Invest Dermatol 2019. [DOI: 10.1016/j.jid.2019.06.066] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
10
|
Nguyen S, Achour A, Souchet L, Vigouroux S, Chevallier P, Furst S, Sirvent A, Bay JO, Socié G, Ceballos P, Huynh A, Cornillon J, Francois S, Legrand F, Yakoub-Agha I, Michel G, Maillard N, Margueritte G, Maury S, Uzunov M, Bulabois CE, Michallet M, Clement L, Dauriac C, Bilger K, Lejeune J, Béziat V, Rocha V, Rio B, Chevret S, Vieillard V. Clinical impact of NK-cell reconstitution after reduced intensity conditioned unrelated cord blood transplantation in patients with acute myeloid leukemia: analysis of a prospective phase II multicenter trial on behalf of the Société Française de Greffe de Moelle Osseuse et Thérapie Cellulaire and Eurocord. Bone Marrow Transplant 2017. [PMID: 28650455 DOI: 10.1038/bmt.2017.122] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
Unrelated cord blood transplantation (UCBT) after a reduced intensity conditioning regimen (RIC) has extended the use of UCB in elderly patients and those with co-morbidities without an HLA-identical donor, although post-transplant relapse remains a concern in high-risk acute myeloid leukemia (AML) patients. HLA incompatibilities between donor and recipient might enhance the alloreactivity of natural killer (NK) cells after allogeneic hematopoietic stem-cell transplantation (HSCT). We studied the reconstitution of NK cells and KIR-L mismatch in 54 patients who underwent a RIC-UCBT for AML in CR in a prospective phase II clinical trial. After RIC-UCBT, NK cells displayed phenotypic features of both activation and immaturity. Restoration of their polyfunctional capacities depended on the timing of their acquisition of phenotypic markers of maturity. The incidence of treatment-related mortality (TRM) was correlated with low CD16 expression (P=0.043) and high HLA-DR expression (P=0.0008), whereas overall survival was associated with increased frequency of NK-cell degranulation (P=0.001). These features reflect a general impairment of the NK licensing process in HLA-mismatched HSCT and may aid the development of future strategies for selecting optimal UCB units and enhancing immune recovery.
Collapse
Affiliation(s)
- S Nguyen
- AP-HP, Hôpital Pitié Salpêtrière (AP-HP), Service d'Hématologie Clinique, Paris, France.,Sorbonne Universités, UPMC Univ Paris 06, INSERM U1135, CNRS ERL8255, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), Paris, France
| | - A Achour
- Sorbonne Universités, UPMC Univ Paris 06, INSERM U1135, CNRS ERL8255, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), Paris, France
| | - L Souchet
- AP-HP, Hôpital Pitié Salpêtrière (AP-HP), Service d'Hématologie Clinique, Paris, France
| | - S Vigouroux
- CHU de Bordeaux Hôpital du Haut-Lévèque, Service d'hématologie clinique et de thérapie cellulaire, Pessac, France
| | - P Chevallier
- CHU de Nantes, Hematology Department, Nantes, France
| | - S Furst
- Institut Paoli Calmettes, Service de greffe de moelle, Marseille, France
| | - A Sirvent
- Centre Hospitalier Universitaire de Montpellier, Montpellier, France
| | - J-O Bay
- CHU Estaing Service d'Hématologie Clinique, Clermont-Ferrand, France
| | - G Socié
- AP-HP, Hôpital Saint-Louis, Service d'Hématologie et de Transplantation, Paris, France
| | | | - A Huynh
- CHU de Toulouse, Hématologie Clinique, Toulouse, France
| | - J Cornillon
- Institut de Cancérologie de la Loire, Service d'Hématologie, Saint-Priest-en-Jarez, France
| | | | - F Legrand
- CHU de Nice, Service d'Hématologie, Nice, France
| | | | - G Michel
- Department of Pediatric Hematology and Oncology, Timone Enfants Hospital and Research Unit EA 3279 Aix-Marseille University, Marseille, France
| | | | | | - S Maury
- Hôpital Henri Mondor, Service d'Hématologie, Créteil, France
| | - M Uzunov
- AP-HP, Hôpital Pitié Salpêtrière (AP-HP), Service d'Hématologie Clinique, Paris, France
| | | | | | - L Clement
- University Hospital de Bordeaux, Bordeaux, France
| | | | - K Bilger
- CHRU de Strasbourg, Strasbourg, France
| | - J Lejeune
- Department de Bioinformatique et Statistique Médicale, Hôpital Saint-Louis, Paris, France
| | - V Béziat
- Sorbonne Universités, UPMC Univ Paris 06, INSERM U1135, CNRS ERL8255, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), Paris, France
| | - V Rocha
- Eurocord Office, Hôpital Saint-Louis, Paris, France
| | - B Rio
- Hôpital Saint-Antoine, Hématologie Clinique et Thérapie Cellulaire, Paris, France
| | - S Chevret
- Department de Bioinformatique et Statistique Médicale, Hôpital Saint-Louis, Paris, France
| | - V Vieillard
- Sorbonne Universités, UPMC Univ Paris 06, INSERM U1135, CNRS ERL8255, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), Paris, France
| |
Collapse
|
11
|
Le Bourgeois A, Labopin M, Blaise D, Ceballos P, Vigouroux S, Peffault De Latour R, Suarez F, Bulabois C, Bay J, Chantepie S, Deconinck E, Daguindau E, Contentin N, Yakoub-Agha I, Cornillon J, Francois S, Turlure P, Charbonnier A, Rohrlich P, N'Guyen S, Maillard N, Marchand T, Mohty M, Chevalllier P. REDUCED INTENSITY (FB2) VS REDUCED TOXICITY MYELOABLATIVE (FB3-4) FLUDARABINE/BUSULFAN-BASED CONDITIONING REGIMENS FOR NON-HODGKIN LYMPHOMA (NHL) ALLOGRAFTED PATIENTS. Hematol Oncol 2017. [DOI: 10.1002/hon.2438_55] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
| | - M. Labopin
- Department of Hematology; Hôpital Saint Antoine; Paris France
| | - D. Blaise
- Centre de Recherche en Cancérologie de Marseille; Department of Hematology; Marseille France
| | - P. Ceballos
- Department of Hematology; CHU Saint Eloi; Montpellier France
| | - S. Vigouroux
- Department of Hematology, CHU de Bordeaux; Bordeaux France
| | | | - F. Suarez
- Department of Hematology; Hôpital Neker-Enfants Malades; Paris France
| | - C. Bulabois
- Department of Hematology, CHU Grenoble; Grenoble France
| | - J. Bay
- Department of Hematology, CHU de Clermont Ferrand; Clermont Ferrand France
| | | | - E. Deconinck
- Department of Hematology, CHU de Besançon; Besançon France
| | - E. Daguindau
- Department of Hematology, CHU de Besançon; Besançon France
| | - N. Contentin
- Department of Hematology, Centre Henri Becquerel; Rouen France
| | | | - J. Cornillon
- Department of Hematology; Institut de Cancérologie Lucien Neuwirth; Saint Etienne France
| | - S. Francois
- Department of Hematology, CHU Angers; Angers France
| | - P. Turlure
- Department of Hematology, CHU de Limoges; Limoges France
| | - A. Charbonnier
- Department of Hematology, CHU d'Amiens Sud; Amiens France
| | - P. Rohrlich
- Department of Hematology, CHU Nice; Nice France
| | - S. N'Guyen
- Department of Hematology; Hôpital Salpétrière; Paris France
| | - N. Maillard
- Department of Hematology; Hôpital La Miletrie; Poitiers France
| | - T. Marchand
- Department of Hematology, CHU Rennes; Rennes France
| | - M. Mohty
- Department of Hematology; Hôpital Saint Antoine; Paris France
| | | |
Collapse
|
12
|
Dörr H, Abend M, Blakely WF, Bolduc DL, Boozer D, Costeira T, Dant T, De Amicis A, De Sanctis S, Dondey M, Drouet M, Entine F, Francois S, Gagna G, Guitard N, Hérodin F, Hoefer M, Lamkowski A, La Sala G, Lista F, Loiacono P, Majewski M, Martigne P, Métivier D, Michel X, Pateux J, Pejchal J, Reeves G, Riccobono D, Sinkorova Z, Soyez L, Stricklin D, Tichy A, Valente M, Woodruff Jr. CR, Zarybnicka L, Port M. Using Clinical Signs and Symptoms for Medical Management of Radiation Casualties – 2015 NATO Exercise. Radiat Res 2017; 187:273-286. [DOI: 10.1667/rr14619.1] [Citation(s) in RCA: 29] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Affiliation(s)
- H. Dörr
- Bundeswehr Institute of Radiobiology affiliated to the University Ulm, Munich, Germany
| | - M. Abend
- Bundeswehr Institute of Radiobiology affiliated to the University Ulm, Munich, Germany
| | - W. F. Blakely
- Armed Forces Radiobiology Research Institute (AFRRI), Uniformed Services, University of the Health Sciences (USUHS), Bethesda, Maryland
| | - D. L. Bolduc
- Armed Forces Radiobiology Research Institute (AFRRI), Uniformed Services, University of the Health Sciences (USUHS), Bethesda, Maryland
| | - D. Boozer
- Armed Forces Radiobiology Research Institute (AFRRI), Uniformed Services, University of the Health Sciences (USUHS), Bethesda, Maryland
| | - T. Costeira
- Armed Forces Radiobiology Research Institute (AFRRI), Uniformed Services, University of the Health Sciences (USUHS), Bethesda, Maryland
| | - T. Dant
- Applied Research Associates, Inc. (ARA), on behalf of (U.S.) Defense Threat Reduction Agency (DTRA), Arlington, Virginia
| | - A. De Amicis
- Army Medical and Veterinary Research Center, Roma, Italy
| | - S. De Sanctis
- Army Medical and Veterinary Research Center, Roma, Italy
| | - M. Dondey
- French Defense Radiation Protection Service (SPRA), Clamart, France
| | - M. Drouet
- Institut de Recherche Biomedicale des Armees, Bretigny-sur-Orge, France
| | - F. Entine
- French Defense Radiation Protection Service (SPRA), Clamart, France
| | - S. Francois
- Institut de Recherche Biomedicale des Armees, Bretigny-sur-Orge, France
| | - G. Gagna
- French Defense Radiation Protection Service (SPRA), Clamart, France
| | - N. Guitard
- Institut de Recherche Biomedicale des Armees, Bretigny-sur-Orge, France
| | - F. Hérodin
- Institut de Recherche Biomedicale des Armees, Bretigny-sur-Orge, France
| | - M. Hoefer
- Armed Forces Radiobiology Research Institute (AFRRI), Uniformed Services, University of the Health Sciences (USUHS), Bethesda, Maryland
| | - A. Lamkowski
- Bundeswehr Institute of Radiobiology affiliated to the University Ulm, Munich, Germany
| | - G. La Sala
- Army Medical and Veterinary Research Center, Roma, Italy
| | - F. Lista
- Army Medical and Veterinary Research Center, Roma, Italy
| | - P. Loiacono
- Army Medical and Veterinary Research Center, Roma, Italy
| | - M. Majewski
- Bundeswehr Institute of Radiobiology affiliated to the University Ulm, Munich, Germany
| | - P. Martigne
- Institut de Recherche Biomedicale des Armees, Bretigny-sur-Orge, France
| | - D. Métivier
- French Defense Radiation Protection Service (SPRA), Clamart, France
| | - X. Michel
- French Defense Radiation Protection Service (SPRA), Clamart, France
| | - J. Pateux
- Institut de Recherche Biomedicale des Armees, Bretigny-sur-Orge, France
| | - J. Pejchal
- Department of Radiobiology, Faculty of Military Health Sciences, University of Defence, Hradec Králové, Czech Republic
| | - G. Reeves
- Applied Research Associates, Inc. (ARA), on behalf of (U.S.) Defense Threat Reduction Agency (DTRA), Arlington, Virginia
| | - D. Riccobono
- Institut de Recherche Biomedicale des Armees, Bretigny-sur-Orge, France
| | - Z. Sinkorova
- Department of Radiobiology, Faculty of Military Health Sciences, University of Defence, Hradec Králové, Czech Republic
| | - L. Soyez
- Institut de Recherche Biomedicale des Armees, Bretigny-sur-Orge, France
| | - D. Stricklin
- Applied Research Associates, Inc. (ARA), on behalf of (U.S.) Defense Threat Reduction Agency (DTRA), Arlington, Virginia
| | - A. Tichy
- Department of Radiobiology, Faculty of Military Health Sciences, University of Defence, Hradec Králové, Czech Republic
| | - M. Valente
- Institut de Recherche Biomedicale des Armees, Bretigny-sur-Orge, France
| | - C. R. Woodruff Jr.
- Armed Forces Radiobiology Research Institute (AFRRI), Uniformed Services, University of the Health Sciences (USUHS), Bethesda, Maryland
| | - L. Zarybnicka
- Department of Radiobiology, Faculty of Military Health Sciences, University of Defence, Hradec Králové, Czech Republic
| | - M. Port
- Bundeswehr Institute of Radiobiology affiliated to the University Ulm, Munich, Germany
| |
Collapse
|
13
|
Legendre G, Faurant MC, Francois S, Bouet PE, Catala L, Lefebvre-Lacoeuille C, Gillard P, Descamps P. Contribution of a Virtual Hysteroscopic Simulator in the Learning of Hysteroscopic Myoma Resection. J Minim Invasive Gynecol 2015; 22:S113. [DOI: 10.1016/j.jmig.2015.08.305] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
14
|
Luiggi S, Melloul E, Briard B, Francois S, Aberkane S, Fihman V, Guillot J, Dannaoui E, Decousser J, Beauvais A, Botterel F. Validation d’un modèle de biofilm mixte Stenotrophomonas maltophilia/Aspergillus fumigatus. J Mycol Med 2015. [DOI: 10.1016/j.mycmed.2015.06.024] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
15
|
Littwitz-Salomon E, Akhmetzyanova I, Vallet C, Francois S, Dittmer U, Gibbert K. Activated regulatory T cells suppress effector NK cell responses by an IL-2-mediated mechanism during an acute retroviral infection. Retrovirology 2015. [PMID: 26220086 PMCID: PMC4518534 DOI: 10.1186/s12977-015-0191-3] [Citation(s) in RCA: 32] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023] Open
Abstract
Background It is well established that effector T cell responses are crucial for the control of most virus infections, but they are often tightly controlled by regulatory T cells (Treg) to minimize immunopathology. NK cells also contribute to virus control but it is not known if their antiviral effect is influenced by virus-induced Tregs as well. We therefore analyzed whether antiretroviral NK cell functions are inhibited by Tregs during an acute Friend retrovirus infection of mice. Results Selective depletion of Tregs by using the transgenic DEREG mouse model resulted in improved NK cell proliferation, maturation and effector cell differentiation. Suppression of NK cell functions depended on IL-2 consumption by Tregs, which could be overcome by specific NK cell stimulation with an IL-2/anti-IL-2 mAb complex. Conclusions The current study demonstrates that virus-induced Tregs indeed inhibit antiviral NK cell responses and describes a targeted immunotherapy that can abrogate the suppression of NK cells by Tregs. Electronic supplementary material The online version of this article (doi:10.1186/s12977-015-0191-3) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Elisabeth Littwitz-Salomon
- Institute of Virology of the University Hospital in Essen, University of Duisburg-Essen, Essen, Germany.
| | - Ilseyar Akhmetzyanova
- Institute of Virology of the University Hospital in Essen, University of Duisburg-Essen, Essen, Germany.
| | - Cecilia Vallet
- Institute of Virology of the University Hospital in Essen, University of Duisburg-Essen, Essen, Germany.
| | - Sandra Francois
- Institute of Virology of the University Hospital in Essen, University of Duisburg-Essen, Essen, Germany.
| | - Ulf Dittmer
- Institute of Virology of the University Hospital in Essen, University of Duisburg-Essen, Essen, Germany.
| | - Kathrin Gibbert
- Institute of Virology of the University Hospital in Essen, University of Duisburg-Essen, Essen, Germany.
| |
Collapse
|
16
|
Gibbert K, Francois S, Sigmund AM, Harper MS, Barrett BS, Kirchning CJ, Lu M, Santiago ML, Dittmer U. Friend retrovirus drives cytotoxic effectors through Toll-like receptor 3. Retrovirology 2014; 11:126. [PMID: 25539593 PMCID: PMC4299798 DOI: 10.1186/s12977-014-0126-4] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/24/2014] [Accepted: 12/05/2014] [Indexed: 12/24/2022] Open
Abstract
Background Pathogen recognition drives host defense towards viral infections. Specific groups rather than single members of the protein family of pattern recognition receptors (PRRs) such as membrane spanning Toll-like receptors (TLRs) and cytosolic helicases might mediate sensing of replication intermediates of a specific virus species. TLR7 mediates host sensing of retroviruses and could significantly influence retrovirus-specific antibody responses. However, the origin of efficient cell-mediated immunity towards retroviruses is unknown. Double-stranded RNA intermediates produced during retroviral replication are good candidates for immune stimulatory viral products. Thus, we considered TLR3 as primer of cell-mediated immunity against retroviruses in vivo. Results Infection of mice deficient in TLR3 (TLR3−/−) with Friend retrovirus (FV) complex revealed higher viral loads during acute retroviral infection compared to wild type mice. TLR3−/− mice exhibited significantly lower expression levels of type I interferons (IFNs) and IFN-stimulated genes like Pkr or Ifi44, as well as reduced numbers of activated myeloid dendritic cells (DCs) (CD86+ and MHC-II+). DCs generated from FV-infected TLR3−/− mice were less capable of priming virus-specific CD8+ T cell proliferation. Moreover, cytotoxicity of natural killer (NK) cells as well as CD8+ T cells were reduced in vitro and in vivo, respectively, in FV-infected TLR3-/- mice. Conclusions TLR3 mediates antiretroviral cytotoxic NK cell and CD8+ T cell activity in vivo. Our findings qualify TLR3 as target of immune therapy against retroviral infections.
Collapse
Affiliation(s)
- Kathrin Gibbert
- Institute for Virology of the University Hospital in Essen, University of Duisburg-Essen, Essen, Germany.
| | - Sandra Francois
- Institute for Virology of the University Hospital in Essen, University of Duisburg-Essen, Essen, Germany.
| | - Anna M Sigmund
- Institute for Medical Microbiology of the University Hospital in Essen, University of Duisburg-Essen, Essen, Germany.
| | - Michael S Harper
- Department of Medicine, University of Colorado Denver, Aurora, CO, 80045, USA.
| | - Bradley S Barrett
- Department of Medicine, University of Colorado Denver, Aurora, CO, 80045, USA.
| | - Carsten J Kirchning
- Institute for Medical Microbiology of the University Hospital in Essen, University of Duisburg-Essen, Essen, Germany.
| | - Mengji Lu
- Institute for Virology of the University Hospital in Essen, University of Duisburg-Essen, Essen, Germany.
| | - Mario L Santiago
- Department of Medicine, University of Colorado Denver, Aurora, CO, 80045, USA.
| | - Ulf Dittmer
- Institute for Virology of the University Hospital in Essen, University of Duisburg-Essen, Essen, Germany.
| |
Collapse
|
17
|
Francois S, Lhomme B, Benderitter M, Gorin NC, Douay L, Larsen A, Forgue-Lafitte ME, Chapel A. OP0018 mi-RNA-150 and seven regulators of mesenchymal stem cells action on colon cancer inflammatory tumour microenvironment. Eur J Cancer 2014. [DOI: 10.1016/j.ejca.2014.03.036] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
18
|
Voswinkel J, Lataillade J, Mothy M, Gorin N, Simon J, Francois S, Benderitter M, Perrot J, Chapel A. Clinical and immunological response to mesenchymal stem cell (MSC) therapy first experiences in irradiation induced colitis. Cytotherapy 2014. [DOI: 10.1016/j.jcyt.2014.01.350] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
19
|
Francois S, Usunier B, Douay L, Benderitter M, Chapel A. Long-term quantitative bio-distribution and side effects of human mesenchymal stem cells (hMSCs) engraftment in NOD/SCID mice following irradiation. Cytotherapy 2014. [DOI: 10.1016/j.jcyt.2014.01.358] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
20
|
Francois S, L'homme B, Benderitter M, Douay L, Chapel A. Mesenchymal stem cells transplants after pelvic radiotherapy limits the development of radiation-induced fibrosis, without promoting the residual tumor growth. Cytotherapy 2014. [DOI: 10.1016/j.jcyt.2014.01.331] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
21
|
Maciejewski M, Avenel-Audran M, Francois S, Schmidt A, Jouen F, Martin L, LeCorre Y. Pemphigoïde bulleuse après greffe allogénique de moelle osseuse. Ann Dermatol Venereol 2013. [DOI: 10.1016/j.annder.2013.09.377] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
22
|
Littwitz E, Francois S, Dittmer U, Gibbert K. Distinct roles of NK cells in viral immunity during different phases of acute Friend retrovirus infection. Retrovirology 2013; 10:127. [PMID: 24182203 PMCID: PMC3826539 DOI: 10.1186/1742-4690-10-127] [Citation(s) in RCA: 33] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/13/2013] [Accepted: 10/29/2013] [Indexed: 12/30/2022] Open
Abstract
BACKGROUND In many virus infections natural killer (NK) cells are critical for the rapid containment of virus replication. Polymorphisms in NK cell receptors as well as viral escape from NK cell responses are associated with pathogenesis and viral loads in HIV-infected individuals, emphasizing their importance in retroviral immunity. In contrast, NK cells of LCMV-infected mice dampened virus-specific T cell responses resulting in impaired virus control. Thus, the exact role of NK cells during different phases of viral infections remains elusive. In this study we characterized the NK cell response at different time points of an acute retroviral infection by using the Friend retrovirus (FV) mouse model. FINDINGS Depletion of NK1.1⁺ cells during the initial phase of FV infection (3 to 4 days post infection) resulted in increased viral loads, which correlated with enhanced target cell killing and elevated NK cell effector functions. At days 7 to 15 post infection, NK and NKT cells did not contribute to anti-retroviral immunity. In the transition phase between acute and chronic infection (30 days post infection), NK and NKT cells exhibited an inhibitory role and their depletion resulted in reduced viral loads and significantly improved FV-specific CD8⁺ T cell responses. CONCLUSIONS Our results demonstrate an opposed activity of NK cells during retroviral infection. They were protective in the initial phase of infection, when adaptive T cell responses were not yet detectable, but were dispensable for viral immunity after T cell expansion. At later time points they exhibited regulatory functions in inhibiting virus-specific CD8⁺ T cell responses.
Collapse
Affiliation(s)
| | | | | | - Kathrin Gibbert
- Institute for Virology of the University Hospital in Essen, University of Duisburg-Essen, Essen, Germany.
| |
Collapse
|
23
|
Francois S, Berendes C, Trilling M, Piehler J, Dittmer U, Gibbert K. 83. Cytokine 2013. [DOI: 10.1016/j.cyto.2013.06.086] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
24
|
Francois S, Peng J, Schwarz T, Duppach J, Gibbert K, Dittmer U, Kraft AR. NK cells improve control of friend virus infection in mice persistently infected with murine cytomegalovirus. Retrovirology 2013; 10:58. [PMID: 23738889 PMCID: PMC3744174 DOI: 10.1186/1742-4690-10-58] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/02/2013] [Accepted: 05/19/2013] [Indexed: 11/10/2022] Open
Abstract
Background Co-infection of HIV patients with cytomegalovirus (CMV) is associated with enhanced AIDS progression and CMV end-organ diseases. On the other hand, persistent CMV infection has recently been shown to decrease tumor relapse and protect against lethal bacterial infection. The influence of persistent CMV on the outcome of an acute retroviral superinfection is still unknown. Results Here we show that a persistent murine CMV (mCMV) infection surprisingly confers higher resistance to a primary Friend retrovirus infection (FV) of mice. Decreased FV titers and augmented FV-specific CD8 T-cell responses were found in mCMV infected mice during primary FV superinfection. NK cells produced higher amounts of IFNgamma after FV infection of persistently mCMV infected mice suggesting that these cells were involved in the ‘protective’ effect. Depletion of NK1.1+ cells or neutralization of IFNgamma during FV superinfection abrogated the mCMV-mediated effect. Conclusion Our data demonstrate for the first time that a persistent CMV infection induces long-lasting NK cell responses that can enhance immunity to primary retroviral infections. To our knowledge, studies investigating primary HIV infection have not analyzed the role of the CMV seropositivity in these patients. Our observations suggest that NK cells in CMV seropositive individuals might contribute to the control of primary HIV infection.
Collapse
Affiliation(s)
- Sandra Francois
- Institute for Virology of the University Hospital in Essen, University of Duisburg-Essen, Essen, Germany.
| | | | | | | | | | | | | |
Collapse
|
25
|
Damaj G, Duhame A, Robin M, Milpied N, Michallet M, Chevallier P, Beguin Y, Nguyen S, Lioure B, Blaise D, Maillard N, Rubio M, Fegueux N, Cornillon J, Francois S, Mohty M, Huyn A, Bulabois C, Fenaux P, Yakoub-Agha I. O-014 Azacitidine versus best supportive care before non-myeloablative allogeneic stem cell transplantation for MDS: A study by the SFGM-TC. Leuk Res 2013. [DOI: 10.1016/s0145-2126(13)70036-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
26
|
Gibbert K, Joedicke JJ, Meryk A, Trilling M, Francois S, Duppach J, Kraft A, Lang KS, Dittmer U. Interferon-alpha subtype 11 activates NK cells and enables control of retroviral infection. PLoS Pathog 2012; 8:e1002868. [PMID: 22912583 PMCID: PMC3415439 DOI: 10.1371/journal.ppat.1002868] [Citation(s) in RCA: 48] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/27/2012] [Accepted: 07/05/2012] [Indexed: 12/17/2022] Open
Abstract
The innate immune response mediated by cells such as natural killer (NK) cells is critical for the rapid containment of virus replication and spread during acute infection. Here, we show that subtype 11 of the type I interferon (IFN) family greatly potentiates the antiviral activity of NK cells during retroviral infection. Treatment of mice with IFN-α11 during Friend retrovirus infection (FV) significantly reduced viral loads and resulted in long-term protection from virus-induced leukemia. The effect of IFN-α11 on NK cells was direct and signaled through the type I IFN receptor. Furthermore, IFN-α11-mediated activation of NK cells enabled cytolytic killing of FV-infected target cells via the exocytosis pathway. Depletion and adoptive transfer experiments illustrated that NK cells played a major role in successful IFN-α11 therapy. Additional experiments with Mouse Cytomegalovirus infections demonstrated that the therapeutic effect of IFN-α11 is not restricted to retroviruses. The type I IFN subtypes 2 and 5, which bind the same receptor as IFN-α11, did not elicit similar antiviral effects. These results demonstrate a unique and subtype-specific activation of NK cells by IFN-α11. The innate immune response mediated by cells such as natural killer (NK) cells can contribute to immunity against viral infections. NK cells can kill virus-infected cells and thus inhibit virus replication and spread during acute infection. However, in infections with retroviruses, like HIV, these cells are not sufficient to prevent pathology. Here, we describe a new strategy to augment natural killer cell responses during virus infections by using a subtype of the type I interferon family as antiviral drug. This therapy strongly activated NK cells and enabled them to control retrovirus as well as herpes virus infections in mice. The new approach might have great potential for the treatment of many infectious and tumor diseases in which natural killer cells play a significant role in immunity.
Collapse
Affiliation(s)
- Kathrin Gibbert
- Institute for Virology of the University Hospital in Essen, University of Duisburg-Essen, Essen, Germany.
| | | | | | | | | | | | | | | | | |
Collapse
|
27
|
Mohty M, Blaise D, Milpied N, Michallet M, Vernant J, Fegueux N, Guilhot F, Rio B, Gratecos N, Cahn J, Socie G, Yakoub-Agha I, Huynh A, Francois S, Bay J, Cordonnier C, Buzyn A, Contentin N, Deconinck E, Chevallier P. Reduced-Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation (allo-SCT) For Patients Aged ≥60 Years: A Retrospective Analysis Of 629 Patients From The Societe Francaise de Greffe de Moelle et de Therapie Cellulaire (SFGM-TC). Biol Blood Marrow Transplant 2010. [DOI: 10.1016/j.bbmt.2009.12.033] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
28
|
Nasef A, Zhang YZ, Mazurier C, Bouchet S, Bensidhoum M, Francois S, Gorin NC, Lopez M, Thierry D, Fouillard L, Chapel A. Selected Stro-1-enriched bone marrow stromal cells display a major suppressive effect on lymphocyte proliferation. Int J Lab Hematol 2009; 31:9-19. [PMID: 19143868 DOI: 10.1111/j.1751-553x.2007.00997.x] [Citation(s) in RCA: 76] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
Mesenchymal stem cells (MSCs) have an immunosuppressive effect and can inhibit the proliferation of alloreactive T cells in vitro and in vivo. Cotransplantation of MSCs and hematopoietic stem cells (HSCs) from HLA-identical siblings has been shown to reduce the incidence of acute graft-vs.-host disease. MSCs are heterogeneous and data on the inhibitory effects of different MSC subsets are lacking. The antigen Stro1 is a marker for a pure primitive MSC subset. We investigated whether Stro-1-enriched induce a more significant suppressive effect on lymphocytes in a mixed lymphocyte reaction (MLR), and whether this action is related to a specific gene expression profile in Stro-1-enriched compared to other MSCs. We demonstrated that the Stro-1-enriched population elicits a significantly more profound dose-dependent inhibition of lymphocyte proliferation in a MLR than MSCs. One thousand expanded Stro-1-enriched induced an inhibitory effect comparable to that of 10 times as many MSCs. Inhibition by Stro-1-enriched was more significant in contact-dependent cultures than in noncontact-dependant cultures at higher ratio. The Stro-1-enriched inhibitory effect in both culture types was linked to increased gene expression for soluble inhibitory factors such as interleukin-8 (IL-8), leukemia inhibitory factor (LIF), indoleamine oxidase (IDO), human leukocyte antigen-G (HLA-G), and vascular cell adhesion molecule (VCAM1). However, tumor growth factor-beta1 (TGF-beta) and IL-10 were only up-regulated in contact-dependant cultures. These results may support using a purified Stro-1-enriched population to augment the suppressive effect in allogeneic transplantation.
Collapse
Affiliation(s)
- A Nasef
- EA 1638 Laboratoire de Thérapie Cellulaire et Radioprotection Accidentelle (LTCRA), Faculté de médecine Saint Antoine, Université Paris VI, Paris, France
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
29
|
Leiba M, Shimoni A, Guilhot F, Martineau G, Renaud M, Francois S, Hardan I, Nagler A. 134: No evidence for increased transplant related toxicity in Ph+ chronic myelogenous leukemia (CML) and acute lymphoblastic leukemia (ALL) with prior exposure to Dasatinib. Biol Blood Marrow Transplant 2007. [DOI: 10.1016/j.bbmt.2006.12.138] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
30
|
Barkholt L, Bregni M, Remberger M, Blaise D, Peccatori J, Massenkeil G, Pedrazzoli P, Zambelli A, Bay JO, Francois S, Martino R, Bengala C, Brune M, Lenhoff S, Porcellini A, Falda M, Siena S, Demirer T, Niederwieser D, Ringdén O. Allogeneic haematopoietic stem cell transplantation for metastatic renal carcinoma in Europe. Ann Oncol 2006; 17:1134-40. [PMID: 16648196 DOI: 10.1093/annonc/mdl086] [Citation(s) in RCA: 74] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/24/2023] Open
Abstract
BACKGROUND An allogeneic antitumour effect has been reported for various cancers. We evaluated the experience of allogeneic haematopoietic stem cell transplantation (HSCT) for renal cell carcinoma (RCC) in 124 patients from 21 European centres. PATIENTS AND METHODS Reduced intensity conditioning and peripheral blood stem cells from an HLA-identical sibling (n = 106), a mismatched related (n = 5), or an unrelated (n = 13) donor were used. Immunosuppression was cyclosporine alone, or combined with methotrexate or mycophenolate mofetil. Donor lymphocyte infusions (DLI) were given to 42 patients. The median follow-up was 15 (range 3-41) months. RESULTS All but three patients engrafted. The cumulative incidence of moderate to severe, grades II-IV acute GVHD was 40% and for chronic GVHD it was 33%. Transplant-related mortality was 16% at one year. Complete (n = 4) or partial (n = 24) responses, median 150 (range 42-600) days post-transplant, were associated with time from diagnosis to HSCT, mismatched donor and acute GVHD II-IV. Factors associated with survival included chronic GVHD (hazards ratio, HR 4.12, P < 0.001), DLI (HR 3.39, P < 0.001), <3 metastatic sites (HR 2.61, P = 0.002) and a Karnofsky score >70 (HR 2.33, P = 0.03). Patients (n = 17) with chronic GVHD and given DLI had a 2-year survival of 70%. CONCLUSION Patients with metastatic RCC, less than three metastatic locations and a Karnofsky score >70% can be considered for HSCT. Posttransplant DLI and limited chronic GVHD improved the patient survival.
Collapse
Affiliation(s)
- L Barkholt
- Division of Clinical Immunology and Centre for Allogeneic Stem Cell Transplantation, Karolinska University Hospital Huddinge, Stockholm, Sweden
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
31
|
Barkholt L, Bregni M, Remberger M, Blaise D, Peccatori J, Massenkeil G, Pedrazzoli P, Zambelli A, Bay JO, Francois S, Martino R, Bengala C, Brune M, Lenhoff S, Porcellini A, Falda M, Siena S, Demirer T, Niederwieser D, Ringden O. European experience of allogeneic hematopoietic stem cell transplantation for metastatic renal carcinoma: On behalf of the french ITAC group and the EBMT Solid Tumour Working Party. Biol Blood Marrow Transplant 2006. [DOI: 10.1016/j.bbmt.2005.11.066] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
32
|
Hunault-Berger M, Tanguy-Schmidt A, Rachieru P, Lévy V, Truchan-Graczyk M, Francois S, Gardembas-Pain M, Dib M, Foussard C, Piard N, Godon A, Solal-Celigny P, Ifrah N. rHuEpo before high-dose therapy allows autologous peripheral stem-cell transplantation without red blood cell transfusion: a pilot study. Bone Marrow Transplant 2005; 35:903-7. [PMID: 15765111 DOI: 10.1038/sj.bmt.1704899] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
To decrease red blood cell (RBC) transfusion requirements during high-dose therapy (HDT) for hematological malignancies, we conducted a pilot study to assess the effect of recombinant human erythropoietin (rHuEpo) given during chemotherapy before HDT and autologous peripheral stem-cell transplantation (APSCT). The transfusion histories of 15 HDT and APSCT for hematological disease performed in 11 consecutive patients who received rHuEpo (10 000 U subcutaneously three times/week) were compared to those of 22 HDT and ASCT performed in 17 consecutive historical controls matched for hematological parameters. rHuEpo increased the hemoglobin (Hb) level from 10.3+/-2.3 g/dl at diagnosis to 12.9+/-2.2 g/dl at the time of HDT in 11 patients; no major adverse effects occurred. Compared to historical controls (95%, 21/22), RBC transfusion requirements were significantly lower for rHuEpo recipients (26%, 4/15) (P=0.00001) and rHuEpo responders (15%, 2/13) (P=0.000002). After HDT and APSCT, fewer RBC transfusions were needed: 3.3, 1.2 and 0.3 RBC units for controls, rHuEpo recipients and rHuEpo responders, respectively (P=0.006 and 0.00002). Therefore, rHuEpo should be administered before, and not after HDT and APSCT, to lower RBC transfusion requirements after HDT and APSCT.
Collapse
|
33
|
Poli-Merol ML, Francois S, Pfliger F, Lefebvre F, Roussel B, Liehn JC, Daoud S. Interest of direct radionuclide cystography in repeated urinary tract infection exploration in childhood. Eur J Pediatr Surg 1998; 8:339-42. [PMID: 9926301 DOI: 10.1055/s-2008-1071228] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Abstract
108 children with repeated urinary tract infection were examined both with direct contrast cystography and radionuclide cystography. There was a good correlation between the two procedures in the majority of the cases (79), but in 21 cases, direct radionuclide cystography alone was positive and for 8 other children, direct contrast cystography showed a low-grade vesico-ureteric reflux even though radionuclide cystography was negative. When comparing the two procedures and taking into consideration the age of the patients we find that radionuclide cystography is more sensitive to detect vesico-ureteric reflux in the younger population (p < 0.02). This advantage is less clear for older children who more often present a low-grade reflux. Low radiation exposure is also a great advantage of radionuclide cystography, but anatomic definition is better with contrast cystography. It seems thus that the two procedures complement rather than rival each other. Their respective interest for evaluation of repeated urinary tract infection in children therefore depends on age, attain-ability of the procedure, and the possibility of a bladder or ureteral abnormality. Quite a few authors consider radionuclide cystography as at least as valid as contrast cystography, and even more sensitive. We have attempted to compare both procedures and to determine their respective role in repeated urinary tract infection exploration.
Collapse
Affiliation(s)
- M L Poli-Merol
- Service de Chirurgie Pédiatrique, American Memorial Hospital, Reims, France
| | | | | | | | | | | | | |
Collapse
|
34
|
Harousseau JL, Cahn JY, Pignon B, Witz F, Milpied N, Delain M, Lioure B, Lamy T, Desablens B, Guilhot F, Caillot D, Abgrall JF, Francois S, Briere J, Guyotat D, Casassus P, Audhuy B, Tellier Z, Hurteloup P, Herve P. Comparison of autologous bone marrow transplantation and intensive chemotherapy as postremission therapy in adult acute myeloid leukemia. The Groupe Ouest Est Leucémies Aiguës Myéloblastiques (GOELAM). Blood 1997; 90:2978-86. [PMID: 9376578] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023] Open
Abstract
Three intensive consolidation strategies are currently proposed to younger adults with acute myeloid leukemia (AML) in first complete remission (CR): allogeneic or autologous bone marrow transplantation (BMT) and intensive consolidation chemotherapy (ICC). Patients aged 15 to 50 years with de novo AML received an induction treatment with 7 days of cytarabine and either idarubicin or rubidazone. After achievement of a CR, patients up to the age of 40 and having an HLA-identical sibling were assigned to undergo an allogeneic BMT. All the other patients received a first course of ICC with high-dose cytarabine and the same anthracycline as for induction. They were then randomly assigned to either receive a second course of ICC with amsacrine and etoposide or a combination of busulfan and cyclosphosphamide followed by an unpurged autologous BMT. Of 517 eligible patients, 367 had a CR, but only 219 (59.5%) actually received the planned intensive postremission treatment (73 allogeneic BMT, 75 autologous BMT, and 71 ICC). With a median follow-up of 62 months, the 4-year disease-free survival (DFS) of the 367 patients in CR was 39.5%. The 4-year overall survival (OS) of the 517 eligible patients was 40.5%. In multivariate analysis, DFS and OS were influenced only by the initial white blood cell count and by the French-American-British classification. The type of postremission therapy had no significant impact on the outcome. There was no difference in the 4-year DFS and OS between 88 patients for whom an allogeneic BMT was scheduled (respectively, 44% and 53%) and 134 patients of the same age category and without an HLA-identical sibling (respectively, 38% and 53%). Similarly, there was no difference in the outcome between autologous BMT and ICC. The 4-year DFS was 44% for the 86 patients randomly assigned to autologous BMT and 40% for the 78 patients assigned to ICC (P = .41). The 4-year OS was similar in the two groups (50% v 54.5%, P = .72). The median duration of hospitalization and thrombocytopenia were longer after autologous BMT (39 v 32 days, P = .006, and 109.5 v 18.5 days, P = .0001, respectively). After a first course of ICC, a second course of chemotherapy is less myelotoxic than an unpurged autologous BMT but yields comparable DFS and OS rates.
Collapse
Affiliation(s)
- J L Harousseau
- Department of Hematology of Centre Hospitalier Universitaire de Nantes, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
35
|
Pignon B, Witz F, Desablens B, Leprise PY, Francois S, Linassier C, Berthou C, Caillot D, Lioure B, Cahn JY, Casassus P, Sadoun A, Audhuy B, Guyotat D, Briere J, Vilque JP, Baranger L, Polin V, Berthaud P, Hurteloup P, Herve P, Harousseau JL. Treatment of acute myelogenous leukaemia in patients aged 50-65: idarubicin is more effective than zorubicin for remission induction and prolonged disease-free survival can be obtained using a unique consolidation course. The Goelam Group. Br J Haematol 1996; 94:333-41. [PMID: 8759894 DOI: 10.1046/j.1365-2141.1996.d01-1803.x] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
From December 1987 to June 1992, 251 patients aged 50-65 with de novo acute myelogenous leukaemia (AML) were recruited to a multi-institutional randomized clinical trial. Induction therapy consisted of Ara-C (200 mg/ m2, continuous infusion, days 1-7) with either zorubicin (ZRB) (200 mg/m2, i.v., days 1-4) or idarubicin (IDR) (8 mg/ m2, i.v., days 1-5). Consolidation therapy consisted of a single course of intensive chemotherapy with high-dose Ara-C (3 g/m2, 3 h infusion, q 12 h, days 1-4) and m-Amsa (100 mg/m2/d, i.v., days 5-7). The complete remission (CR) rate was (73%) with Ara-C/ IDR versus (60%) with Ara-C/ZRB (P = 0.033). In multivariate analysis, factors found to be significant in predicting CR were normal karyotype and treatment with IDR. With a median follow-up of 73 months, the median disease-free survival (DFS) duration of all CR patients and the probability of CR at 6 years were 17 months and 29%. In multivariate analysis the only factor associated with an increased DFS duration was a normal karyotype. The median event-free survival (EFS) duration for all evaluable patients and the median overall survival duration for all eligible patients were respectively 7 and 12 months without any difference between induction arms. The study shows that in patients aged 50-65 idarabicin is more effective than zorubicin for remission induction. However, the type of anthracycline did not influence overall survival duration. Using a unique consolidation course, we observed a prolonged DFS which compares favourably with results obtained with more prolonged consolidation therapy or maintenance treatment.
Collapse
Affiliation(s)
- B Pignon
- Unité d'Hématologie Clinique, Hôpital R. Debré Reims, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
36
|
Saad R, Vincent JF, Cimon B, de Gentile L, Francois S, Bouachour G, Ifrah N. Pulmonary toxoplasmosis after allogeneic bone marrow transplantation: case report and review. Bone Marrow Transplant 1996; 18:211-2. [PMID: 8832018] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
We report an isolated case of toxoplasma pneumonitis in a 27-year-old man. This acute infection occurred after induction chemotherapy for AMLo relapsing 3 years post-allogeneic BMT. The detection of Toxoplasma gondii in the bronchoalvolar lavage (BAL), by culture in fibroblast cell line MRC5 enabled us to make the diagnosis. Pyrimethamine and sulfadiazine were effective.
Collapse
Affiliation(s)
- R Saad
- Department of Hematology, CHU, Angers, France
| | | | | | | | | | | | | |
Collapse
|
37
|
Abstract
We report the results of a study concerning 80 infants undergoing a pyloromyotomy over a 3-and-a-half-year period. 40 infants had a right upper quadrant transverse rectus incision and 40 infants had an umbilical fold incision. Morbidity and cosmetic aspect of the two techniques were compared. We insist on the umbilical fold incision which presents the same advantages as the classic one and a better cosmetic result.
Collapse
Affiliation(s)
- M L Poli-Merol
- Department of Pediatric Surgery, American Memorial Hospital, Reims, France
| | | | | | | | | | | |
Collapse
|
38
|
Juge-Morineau N, Mellerin MP, Francois S, Rapp MJ, Harousseau JL, Amiot M, Bataille R. High incidence of deletions but infrequent inactivation of the retinoblastoma gene in human myeloma cells. Br J Haematol 1995; 91:664-7. [PMID: 8555072 DOI: 10.1111/j.1365-2141.1995.tb05365.x] [Citation(s) in RCA: 27] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
We have studied the retinoblastoma (RB-1) susceptibility gene status and pRB expression in 22 human myeloma cell lines (HMCL) and in 10 patients with advanced multiple myeloma (MM). Deletions of the RB-1 gene were observed in 81% (17/21) of the informative HMCL, regardless of their paracrine or autocrine interleukin-6 (IL-6) status. Among the deleted HMCL, only one (U266) had a biallelic deletion and lacked pRB expression. Monoallelic deletions had no consequence on the RB-1 gene activation and pRB expression. One patient of 10 presented the same biallclic deletion as U266 and six of 10 had monoallelic deletions. We conclude that monoallelic deletions of the RB-1 gene are frequent in HMCL and MM patients but have no consequence on gene activation and pRB expression.
Collapse
Affiliation(s)
- N Juge-Morineau
- Laboratoire d'Hématologie, Institut de Biologie, Nantes, France
| | | | | | | | | | | | | |
Collapse
|
39
|
Baranger L, Szapiro N, Gardais J, Hillion J, Derre J, Francois S, Blanchet O, Boasson M, Berger R. Translocation t(5;12)(q31-q33;p12-p13): a non-random translocation associated with a myeloid disorder with eosinophilia. Br J Haematol 1994; 88:343-7. [PMID: 7803280 DOI: 10.1111/j.1365-2141.1994.tb05029.x] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
A t(5;12)(q33;p13) translocation has been detected in two patients with myeloid disorder and eosinophilia. Six other patients with haematological disease with eosinophilia with similar translocation have been published previously. The existence of a new entity, a myeloproliferative disorder with eosinophilia and t(5;12) (q31-q33;p12-p13), is suggested by the results of the present study.
Collapse
Affiliation(s)
- L Baranger
- Laboratoire de Génétique, CHU Angers, France
| | | | | | | | | | | | | | | | | |
Collapse
|
40
|
|